In 539 untreated patients with higher-risk MDS, magrolimab plus azacitidine did not improve complete remission (21.3% vs 23.6%) or median overall survival (15.9 vs 18.6 months; HR 1.203) vs placebo plus azacitidine, and had more fatal adverse events (15.2% vs 9.8%).
RCTn = 539
Sallman et al. Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study